Summary
0.55 0.03(5.33%)05/10/2024
Sangamo Therapeutics Inc (SGMO)
Sangamo Therapeutics Inc (SGMO)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.55 | 4.83 | -3.62 | 10.93 | 28.55 | -57.49 | -95.23 | -96.42 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 0.54 | |
| Open | 0.52 | |
| High | 0.56 | |
| Low | 0.51 | |
| Volume | 1,586,331 | |
| Change | 0.01 | |
| Change % | 2.55 | |
| Avg Volume (20 Days) | 1,098,452 | |
| Volume/Avg Volume (20 Days) Ratio | 1.44 | |
| 52 Week Range | 0.29 - 1.67 | |
| Price vs 52 Week High | -67.67% | |
| Price vs 52 Week Low | 86.17% | |
| Range | 3.61 | |
| Gap Up/Down | -0.04 | |
Fundamentals | ||
| Market Capitalization (Mln) | 114 | |
| EBIDTA | -210,931,744 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 3.50 | |
| Book Value | 0.4650 | |
| Earnings Per Share | -1.4800 | |
| EPS Estimate Current Quarter | -0.2600 | |
| EPS Estimate Next Quarter | -0.1100 | |
| EPS Estimate Current Year | -0.5000 | |
| EPS Estimate Next Year | -0.2700 | |
| Diluted EPS (TTM) | -1.4800 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -98.0811 | |
| Return on asset (TTM) | -0.1760 | |
| Return on equity (TTM) | -1.3647 | |
| Revenue TTM | 18,756,000 | |
| Revenue per share TTM | 0.1060 | |
| Quarterly Revenue Growth (YOY) | -0.9970 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -138,599,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.3519 | |
| Revenue Enterprise Value | 0.3924 | |
| EBITDA Enterprise Value | -0.7145 | |
| Shares | ||
| Shares Outstanding | 207,496,000 | |
| Shares Float | 147,499,340 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.06 | |
| Insider (%) | 7.71 | |
| Institutions (%) | 55.46 | |
05/09 18:26 EST - Zacks Investment Research
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to earnings of $0.12 per share a year ago.
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to earnings of $0.12 per share a year ago.
05/02 16:15 EST - Business Wire
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast.
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast.
04/22 16:35 EST - Business Wire
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Neurology Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at ASGCT.
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Neurology Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at ASGCT.
03/12 18:30 EST - Business Wire
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast.
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast.
01/08 08:26 EST - MarketBeat
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic differences.
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic differences.
10/26 11:22 EST - Zacks Investment Research
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10/25 16:15 EST - Business Wire
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast.
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast.
10/24 02:01 EST - Business Wire
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg Research at ESGCT.
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg Research at ESGCT.
09/20 16:15 EST - Business Wire
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit.
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit.
08/25 13:38 EST - InvestorPlace
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
Rare disease stocks have a difficult task. The rarer a disease is, the less public research goes into studying it.
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
Rare disease stocks have a difficult task. The rarer a disease is, the less public research goes into studying it.
08/08 18:56 EST - Zacks Investment Research
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.29 per share a year ago.
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.29 per share a year ago.
04/16 06:30 EST - InvestorPlace
7 Sorry Pharma Stocks to Sell in April Before It's Too Late
Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can also mean heavy expenditures on research and testing for a drug that may not perform as well as scientists hope.
7 Sorry Pharma Stocks to Sell in April Before It's Too Late
Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can also mean heavy expenditures on research and testing for a drug that may not perform as well as scientists hope.
03/23 02:52 EST - Seeking Alpha
Sangamo: Hemophilia A Program With Pfizer Key To Success
Final results from the phase 3 AFFINE trial using giroctocogene fitelparvovec for the treatment of patients with Hemophilia A are expected in the 1st half of 2024. If phase 3 trial is successful, Pfizer will be able to file BLA to the FDA of giroctocogene fitelparvovec for the treatment of patients with Hemophilia A 2nd half 2024.
Sangamo: Hemophilia A Program With Pfizer Key To Success
Final results from the phase 3 AFFINE trial using giroctocogene fitelparvovec for the treatment of patients with Hemophilia A are expected in the 1st half of 2024. If phase 3 trial is successful, Pfizer will be able to file BLA to the FDA of giroctocogene fitelparvovec for the treatment of patients with Hemophilia A 2nd half 2024.
02/23 11:54 EST - PennyStocks
Best Penny Stocks To Buy? 3 To Watch With Targets Up To 400%
Analysts like these penny stocks but is it time to buy or not? The post Best Penny Stocks To Buy?
Best Penny Stocks To Buy? 3 To Watch With Targets Up To 400%
Analysts like these penny stocks but is it time to buy or not? The post Best Penny Stocks To Buy?
02/22 21:15 EST - Seeking Alpha
Sangamo Therapeutics, Inc. (SGMO) Q4 2022 Earnings Call Transcript
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q4 2022 Results Conference Call February 22, 2023 4:30 PM ET Company Participants Louise Wilkie - VP of IR and Corporate Communications Sandy Macrae - Chief Executive Officer Mark McClung - Chief Operating Officer Prathyusha Duraibabu - Chief Financial Officer Jason Fontenot - Chief Scientific Officer Nathalie Dubois-Stringfellow - Chief Development Officer Bettina Cockroft - Chief Medical Officer Andy Ramelmeier - Head of Technical Operations Conference Call Participants Ritu Baral - Cowen Yanan Zhu - Wells Fargo Mary Kay - Bank of America Merrill Lynch Ben Burnett - Stifel Gena Wang - Barclays Nicole Germino - Truist Maury Raycroft - Jefferies Operator Good day, ladies and gentlemen, and thank you, for standing by. Welcome to the Sangamo Fourth Quarter 2022 Earnings Conference Call.
Sangamo Therapeutics, Inc. (SGMO) Q4 2022 Earnings Call Transcript
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q4 2022 Results Conference Call February 22, 2023 4:30 PM ET Company Participants Louise Wilkie - VP of IR and Corporate Communications Sandy Macrae - Chief Executive Officer Mark McClung - Chief Operating Officer Prathyusha Duraibabu - Chief Financial Officer Jason Fontenot - Chief Scientific Officer Nathalie Dubois-Stringfellow - Chief Development Officer Bettina Cockroft - Chief Medical Officer Andy Ramelmeier - Head of Technical Operations Conference Call Participants Ritu Baral - Cowen Yanan Zhu - Wells Fargo Mary Kay - Bank of America Merrill Lynch Ben Burnett - Stifel Gena Wang - Barclays Nicole Germino - Truist Maury Raycroft - Jefferies Operator Good day, ladies and gentlemen, and thank you, for standing by. Welcome to the Sangamo Fourth Quarter 2022 Earnings Conference Call.
02/22 18:49 EST - Zacks Investment Research
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
02/22 11:19 EST - Zacks Investment Research
Here's Why Sangamo (SGMO) is Poised for a Turnaround After Losing -17.68% in 4 Weeks
The heavy selling pressure might have exhausted for Sangamo (SGMO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here's Why Sangamo (SGMO) is Poised for a Turnaround After Losing -17.68% in 4 Weeks
The heavy selling pressure might have exhausted for Sangamo (SGMO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
02/21 09:16 EST - MarketBeat
There's a Lot of Upside For Emerging Gene-Editing Companies
Gene editing may be a relatively new industry, but it already has a lot of promise, especially for savvy biotech investors. Several gene editing companies have notable upsides, meaning that no matter how good or bad they might be doing right now, there is likely much more to come.
There's a Lot of Upside For Emerging Gene-Editing Companies
Gene editing may be a relatively new industry, but it already has a lot of promise, especially for savvy biotech investors. Several gene editing companies have notable upsides, meaning that no matter how good or bad they might be doing right now, there is likely much more to come.
02/10 11:01 EST - The Motley Fool
Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week
These cutting-edge biotech companies quickly fell out of favor with investors this week.
Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week
These cutting-edge biotech companies quickly fell out of favor with investors this week.
01/30 19:10 EST - InvestorPlace
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.